Q32 Bio Inc.

QTTB • Biotechnology

$11.99

▼ -0.81 (-6.33%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$202.25M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Stable or improving margins · 55.5%Reasonable earnings multiple · 1.37Manageable debt level · 0.37Healthy liquidity · 4.85Negative growth trend

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$11.99

Change-6.33%

Market Cap$202.25M

52W Range1.57 - 23.57

Beta-0.33

Gross Margin99.27%

Oper. Margin31.45%

Profit Margin55.49%

Debt/Eq0.37

Current Ratio4.85

Quick Ratio4.85

Target$38.00

Price$11.99

Change-6.33%

Market Cap$202.25M

52W Range1.57 - 23.57

Beta-0.33

Gross Margin99.27%

Oper. Margin31.45%

Profit Margin55.49%

Debt/Eq0.37

Current Ratio4.85

Quick Ratio4.85

Target$38.00

Target Upside216.93%

Target Median$36.00

Target Range14.00 - 66.00

Volume29.34K

Avg Volume1.50M

EPS Surprise-0.02

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

90/100

Financial Strength

Debt, cash, stability

94/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Stable or improving margins · 55.5%Reasonable earnings multiple · 1.37Manageable debt level · 0.37Healthy liquidity · 4.85Negative growth trend

Analyst view

Analyst sentiment and price target

QTTB

Analyst sentiment

Based on 8 analyst votes · 2026-09-04

75/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$14.00

Mean

$39.00

Median

$38.00

High

$66.00

Company Overview

IPO: 3/28/2018

Industry: Biotechnology

P/B i: 0.97

Debt / Equity i: 0.37

Operating Margin: 31.45%

Net Margin: 55.49%

ROE i: -

ROIC: -

Financial Health

Score19 / 20

Debt / Equity: 0.37

Current Ratio: 4.85

Quick Ratio: 4.85

Status: Strong

Insider Transactions

Recent executive and insider activity

Thistle Mary

Transaction: 06/12/2026

BUY

Change

+10,826

Price

$12.64

Filing

07/21/2026

Type

BUY

GRAYZEL DAVID S.

Transaction: 06/12/2026

BUY

Change

+10,826

Price

$12.64

Filing

07/21/2026

Type

BUY

Manke Isaac

Transaction: 06/12/2026

BUY

Change

+10,826

Price

$12.64

Filing

07/21/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Thistle Mary	BUY	+10,826	$12.64	06/12/2026	07/21/2026
GRAYZEL DAVID S.	BUY	+10,826	$12.64	06/12/2026	07/21/2026
Manke Isaac	BUY	+10,826	$12.64	06/12/2026	07/21/2026
Xu Diyong	BUY	+10,826	$12.64	06/12/2026	07/21/2026
Iwicki Mark T	BUY	+10,826	$12.64	06/12/2026	07/21/2026
LAPORTE KATHLEEN	BUY	+10,826	$12.64	06/12/2026	07/21/2026
Lundberg Sven Ante	BUY	+10,826	$12.64	06/12/2026	07/21/2026
TZIANABOS ARTHUR	BUY	+10,826	$12.64	06/12/2026	07/21/2026
Kalowski Lee	BUY	+53,250	Not reported	07/16/2026	07/20/2026
Morrison Jodie Pope	BUY	+132,000	Not reported	07/16/2026	07/20/2026
Violette Shelia M.	BUY	+37,500	Not reported	07/16/2026	07/20/2026
Manke Isaac	SELL	-53,521	$2.80	06/30/2026	07/02/2026
Manke Isaac	BUY	+53,521	$2.80	06/30/2026	07/02/2026
Lundberg Sven Ante	BUY	+9,810	$12.64	06/12/2026	06/16/2026
Xu Diyong	BUY	+9,810	$12.64	06/12/2026	06/16/2026
Thistle Mary	BUY	+9,810	$12.64	06/12/2026	06/16/2026
GRAYZEL DAVID S.	BUY	+9,810	$12.64	06/12/2026	06/16/2026
TZIANABOS ARTHUR	BUY	+9,810	$12.64	06/12/2026	06/16/2026
Manke Isaac	BUY	+9,810	$12.64	06/12/2026	06/16/2026
Iwicki Mark T	BUY	+9,810	$12.64	06/12/2026	06/16/2026

About the Company

Q32 Bio Inc.

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

Source - link

Peers

ANTX BOLD GBIO INTS ITRM NXTC PSTV SABS SONN VRCA

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Q32 Bio Inc. $QTTB Stock Position Increased by Atlas Venture Life Science Advisors LLC

Atlas Venture Life Science Advisors LLC grew its position in Q32 Bio Inc. (NASDAQ: QTTB) by 29.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,717,106 shares of the company's stock after purchasing an additional 625,000 shares during the period. Q32 Bio makes

Defense World

Q32 Bio to Participate in Upcoming September Investor Conferences

WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026Fireside Chat Presentation Time: 3:45 p.m.

PRNewsWire

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing -- -- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year -- -- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development -- -- Completed $200 million public offering in July 2026 -- -- Cash and cash equivalents of $106.3 million as of June 30, 2026, combined with proceeds from July 2026 public offering, are expected to provide financial runway through Phase 3 topline results from planned registration-directed program -- WALTHAM, Mass., Aug. 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.

PRNewsWire

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-05	-0.52	-0.54	-0.02
2026-03-10	-0.85	3.65	4.5
2025-11-13	-1.39	-0.6	0.79
2025-08-06	-1.14	-0.78	0.36
2025-05-08	-1.23	-0.9	0.33
2025-03-11	-1.25	-1.16	0.09
2024-11-07	-1.41	-1.46	-0.05
2024-08-08	-1	-1.42	-0.42
2024-05-09	-1.42	-13.15	-11.73
2024-03-13	-0.3	-0.28	0.02
2023-11-14	-0.42	-0.57	-0.15
2023-07-27	-8.55	-10.98	-2.43